Edition:
India

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

14.88EUR
21 Aug 2018
Change (% chg)

€1.41 (+10.47%)
Prev Close
€13.47
Open
€13.88
Day's High
€14.88
Day's Low
€13.83
Volume
775,671
Avg. Vol
174,244
52-wk High
€19.42
52-wk Low
€9.02

Chart for

About

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modi... (more)

Overall

Beta: 1.23
Market Cap(Mil.): €325.29
Shares Outstanding(Mil.): 24.55
Dividend: --
Yield (%): --

Financials

BRIEF -Medigene Raises 2018 Guidance After H1 Results

* NOW EXPECTS TO GENERATE TOTAL 2018 REVENUE OF BETWEEN EUR 9.5 - 10.5 MILLION

07 Aug 2018

German stocks - Factors to watch on May 15

BERLIN/FRANKFURT, May 15 The following are some of the factors that may move German stocks on Tuesday:

15 May 2018

Medigene in for up to $1.5 billion under broader pact with Bluebird Bio

FRANKFURT German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

14 May 2018

UPDATE 1-Medigene in for up to $1.5 bln under broader pact with Bluebird Bio

* Shares up 8 pct (Adds shares, background on technology, analyst comment)

14 May 2018

Medigene broadens alliance on T-cell receptors with Bluebird Bio

FRANKFURT, May 14 German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

14 May 2018

BRIEF-Medigene AG Medigene Appoints Dr. Kai Pinkernell To Executive Management Board As Cmo/Cdo

* MEDIGENE AG: MEDIGENE APPOINTS DR. KAI PINKERNELL TO EXECUTIVE MANAGEMENT BOARD AS CMO/CDO Source text for Eikon: Further company coverage:

11 Apr 2018

BRIEF-Medigene AG Says ‍Planned 2018 EBITDA Loss Of EUR 21 - 23 Mln​

* PTA-NEWS: MEDIGENE AG: MEDIGENE PUBLISHES 2017 ANNUAL REPORT AND ANNOUNCES START OF CLINICAL TRIAL WITH TCR IMMUNOTHERAPY MDG1011

22 Mar 2018

Earnings vs. Estimates